SANUWAVE Health Posts 11.43% ROIC Below 12.87% WACC
SNWV•SANUWAVE Health’s ROIC of 11.43% falls short of its 12.87% WACC, yielding a ROIC-to-WACC ratio of 0.89, indicating negative economic value creation. Peers such as TSS and Rafarma report even lower ratios of 0.59 and 0.39, while Aspen Group and Pressure BioSciences achieve positive returns with ratios above 1.40.
1. Capital Efficiency Assessment
SANUWAVE Health recorded a Return on Invested Capital of 11.43% against a weighted average cost of capital of 12.87%, resulting in a ROIC-to-WACC ratio of 0.89. This gap shows each dollar invested yields returns below the company’s financing costs, signaling economic value destruction.
2. Peer Benchmarking
Within the medical technology sector, TSS and Rafarma exhibit ROIC-to-WACC ratios of 0.59 and 0.39 respectively, reflecting deeper returns deficits. In contrast, Aspen Group attains a 1.55 ratio and Pressure BioSciences posts 1.42, highlighting superior capital efficiency and value creation.
3. Implications for Value Creation
A ratio below 1.0 underscores the urgency for SANUWAVE Health to either lower its capital costs or enhance operational profitability. Improvement strategies may include optimizing funding structures, streamlining R&D investments, or driving higher-margin product adoption to reverse economic value losses.
